Header Logo

Kathleen Moore

TitleProf
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentGynecologic Oncology
AddressSOCC 5050
800 NE 10th St
Oklahoma City OK 73104
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    UG1CA233193     (MOORE, KATHLEEN N.)Mar 7, 2019 - Feb 28, 2025
    NIH
    A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical Trials
    Role: Principal Investigator
    R01CA200126     (BENBROOK, DORIS MANGIARACINA)Jun 1, 2016 - May 31, 2022
    NIH
    Targeting HPV Consequences in a Cervical Cancer Clinical Trial
    Role: Co-Principal Investigator
    U10CA180798     (MANNEL, ROBERT S)Apr 24, 2014 - Feb 28, 2019
    NIH
    Lead Academic Participating Site for the Development and Conduct of NCTN Trials
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Moore KN, Mirza MR, Gourley C, Pignata S, Lorusso D, Monk BJ, Sehouli J, Schilder JM, D'Esquermes N, Gonz?lez-Mart?n A. Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe. Int J Gynecol Cancer. 2024 Aug 20. PMID: 39164040.
      Citations:    Fields:    
    2. Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Mirza MR, Kurtz JE, Okamoto A, Moore K, Kridelka F, McNeish I, Reuss A, Votan B, du Bois A, Mahner S, Ray-Coquard I, Kohn EC, Berek JS, Tan DSP, Colombo N, Zang R, Concin N, O'Donnell D, Rauh-Hain A, Herrington CS, Marth C, Poveda A, Fujiwara K, Stuart GCE, Oza AM, Bookman MA. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol. 2022 08; 23(8):e374-e384. PMID: 35901833.
      Citations: 33     Fields:    Translation:Humans
    3. Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Provencher D, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Drochýtek V, Barlin JN, Van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Moore K, Marme F, Westin SN, McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022 Jun 06; JCO2201003. PMID: 35658487.
      Citations: 84     Fields:    Translation:HumansCTClinical Trials
    4. Chen X, Wang X, Zhang K, Fung KM, Thai TC, Moore K, Mannel RS, Liu H, Zheng B, Qiu Y. Recent advances and clinical applications of deep learning in medical image analysis. Med Image Anal. 2022 07; 79:102444. PMID: 35472844.
      Citations: 115     Fields:    Translation:Humans
    5. LaFargue CJ, Handley KF, Fleming ND, Nick AM, Chelariu-Raicu A, Fellman B, Castellano T, Ogasawara A, Hom-Tedla M, Blake EA, da Costa AABA, Crim AK, Rauh-Hain A, Westin SN, Coleman RL, Matsuo K, Baiocchi G, Hasegawa K, Moore K, Sood AK. Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecol Oncol. 2022 04; 165(1):82-89. PMID: 35216808.
      Citations: 2     Fields:    Translation:Humans
    6. Chakravarty D, Johnson A, Sklar J, Lindeman NI, Moore K, Ganesan S, Lovly CM, Perlmutter J, Gray SW, Hwang J, Lieu C, André F, Azad N, Borad M, Tafe L, Messersmith H, Robson M, Meric-Bernstam F. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2022 04 10; 40(11):1231-1258. PMID: 35175857.
      Citations: 60     Fields:    Translation:Humans
    7. Moore KN, du Bois A. Homologous recombination deficiency testing in first-line ovarian cancer. Ann Oncol. 2022 03; 33(3):231-233. PMID: 35017033.
      Citations: 1     Fields:    Translation:Humans
    8. Moore KN, Chambers SK, Hamilton EP, Chen LM, Oza AM, Ghamande SA, Konecny GE, Plaxe SC, Spitz DL, Geenen JJJ, Troso-Sandoval TA, Cragun JM, Rodrigo Imedio E, Kumar S, Mugundu GM, Lai Z, Chmielecki J, Jones SF, Spigel DR, Cadoo KA. Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. Clin Cancer Res. 2022 01 01; 28(1):36-44. PMID: 34645648.
      Citations: 35     Fields:    Translation:Humans
    9. Liu J, Burris H, Wang JS, Barroilhet L, Gutierrez M, Wang Y, Vaze A, Commerford R, Royer-Joo S, Choeurng V, Humke E, Moore K. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2021 12; 163(3):473-480. PMID: 34627611.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    10. Vergote I, Ray-Coquard I, Anderson DM, Cantuaria G, Colombo N, Garnier-Tixidre C, Gilbert L, Harter P, Hettle R, Lorusso D, Mäenpää J, Marth C, Matsumoto K, Ouwens M, Poveda A, Raspagliesi F, Rhodes K, Rubio Pérez MJ, Shapira-Frommer R, Shikama A, Sikorska M, Moore K, DiSilvestro P. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. Eur J Cancer. 2021 11; 157:415-423. PMID: 34597975.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    11. Moore KN, Hong DS, Patel MR, Pant S, Ulahannan SV, Jones S, Meric-Bernstam F, Wang JS, Aljumaily R, Hamilton EP, Wittchen ES, Wang X, Lin AB, Bendell JC. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Target Oncol. 2021 09; 16(5):569-589. PMID: 34559360.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    12. Colombo N, Moore K, Scambia G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Kim JW, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. Gynecol Oncol. 2021 10; 163(1):41-49. PMID: 34353615.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    13. Jacobson D, Moore K, Gunderson C, Rowland M, Austin R, Honap TP, Xu J, Warinner C, Sankaranarayanan K, Lewis CM. Shifts in gut and vaginal microbiomes are associated with cancer recurrence time in women with ovarian cancer. PeerJ. 2021; 9:e11574. PMID: 34178459.
      Citations: 13     Fields:    
    14. Moore KN. PARP inhibitor associated treatment related myeloid neoplasms: What was a "Rare" complication may be less so. Gynecol Oncol. 2021 06; 161(3):639-641. PMID: 34049655.
      Citations: 1     Fields:    Translation:Humans
    15. Falchook G, Infante J, Arkenau HT, Patel MR, Dean E, Borazanci E, Brenner A, Cook N, Lopez J, Pant S, Frankel A, Schmid P, Moore K, McCulloch W, Grimmer K, O'Farrell M, Kemble G, Burris H. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors. EClinicalMedicine. 2021 Apr; 34:100797. PMID: 33870151.
      Citations: 79     
    16. Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol. 2021 06; 32(6):757-765. PMID: 33667670.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    17. Hossen MN, Elechalawar CK, Sjoelund V, Moore K, Mannel R, Bhattacharya R, Mukherjee P. Experimental conditions influence the formation and composition of the corona around gold nanoparticles. Cancer Nanotechnol. 2021; 12(1):1. PMID: 33456622.
      Citations: 8     
    18. Morice PM, Leary A, Dolladille C, Chrétien B, Poulain L, González-Martín A, Moore K, O'Reilly EM, Ray-Coquard I, Alexandre J. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021 Feb; 8(2):e122-e134. PMID: 33347814.
      Citations: 82     Fields:    Translation:Humans
    19. Eskander RN, Pothuri B, Randall L, O'Malley D, Slomovitz B, Moore K, Coleman R, Herzog T, Monk BJ, Copeland L. Clinical trials, adaptability and the COVID-19 pandemic. Gynecol Oncol Rep. 2021 Feb; 35:100680. PMID: 33319009.
      Citations: 1     
    20. Muston D, Hettle R, Monberg M, McLaurin KK, Gao W, Swallow E, Zhang S, Kalemaj I, Signorovitch J, Moore K. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. Gynecol Oncol. 2020 11; 159(2):491-497. PMID: 32951894.
      Citations: 13     Fields:    Translation:Humans
    21. Chen X, Liu W, Thai TC, Castellano T, Gunderson CC, Moore K, Mannel RS, Liu H, Zheng B, Qiu Y. Developing a new radiomics-based CT image marker to detect lymph node metastasis among cervical cancer patients. Comput Methods Programs Biomed. 2020 Dec; 197:105759. PMID: 33007594.
      Citations: 8     Fields:    Translation:Humans
    22. Rischin D, Gil-Martin M, González-Martin A, Braña I, Hou JY, Cho D, Falchook GS, Formenti S, Jabbour S, Moore K, Naing A, Papadopoulos KP, Baranda J, Fury W, Feng M, Stankevich E, Li J, Yama-Dang NA, Yoo SY, Lowy I, Mathias M, Fury MG. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. Gynecol Oncol. 2020 11; 159(2):322-328. PMID: 32917410.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    23. Rimel BJ, Dockery L, Randall LM, Moore K. Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer. Future Oncol. 2020 Nov; 16(33):2701-2711. PMID: 32880196.
      Citations:    Fields:    Translation:Humans
    24. Oza AM, Estevez-Diz M, Grischke EM, Hall M, Marmé F, Provencher D, Uyar D, Weberpals JI, Wenham RM, Laing N, Tracy M, Freshwater T, Lee MA, Liu J, Qiu J, Rose S, Rubin EH, Moore K. A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. Clin Cancer Res. 2020 09 15; 26(18):4767-4776. PMID: 32611648.
      Citations: 60     Fields:    Translation:HumansCTClinical Trials
    25. Moore KN, Birrer MJ, Marsters J, Wang Y, Choi Y, Royer-Joo S, Lemahieu V, Armstrong K, Cordova J, Samineni D, Schuth E, Vaze A, Maslyar D, Humke EW, Hamilton EP, Liu JF. Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2020 09; 158(3):631-639. PMID: 32534811.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    26. Hamilton E, O'Malley DM, O'Cearbhaill R, Cristea M, Fleming GF, Tariq B, Fong A, French D, Rossi M, Brickman D, Moore K. Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 09; 158(3):640-645. PMID: 32513564.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    27. Pothuri B, Alvarez Secord A, Armstrong DK, Chan J, Fader AN, Huh W, Kesterson J, Liu JF, Moore K, Westin SN, Naumann RW. Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. Gynecol Oncol. 2020 07; 158(1):16-24. PMID: 32386911.
      Citations: 25     Fields:    Translation:HumansPHPublic Health
    28. Wise HC, Iyer GV, Moore K, Temkin SM, Gordon S, Aghajanian C, Grisham RN. Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models. Sci Rep. 2019 12 11; 9(1):18882. PMID: 31827119.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    29. Perkins V, Moore K, Vesely S, Matsuo K, Mostofizadeh S, Sims TT, Lea J, Barnes D, Chen S, Carlson M, Roman L, Monk BJ, Holman LL. Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy. Gynecol Oncol. 2020 01; 156(1):100-106. PMID: 31810653.
      Citations: 9     Fields:    Translation:Humans
    30. Papadopoulos KP, Johnson ML, Lockhart AC, Moore K, Falchook GS, Formenti SC, Naing A, Carvajal RD, Rosen LS, Weiss GJ, Leidner RS, Li J, Paccaly A, Feng M, Stankevich E, Lowy I, Fury MG, Crittenden MR. First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. Clin Cancer Res. 2020 03 01; 26(5):1025-1033. PMID: 31796520.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    31. Moore KN, Miller A, Bell-McGuinn KM, Schilder RJ, Walker JL, O'Cearbhaill RE, Guntupalli SR, Armstrong DK, Hagemann AR, Gray HJ, Duska LR, Mathews CA, Chen A, O'Malley D, Gordon S, Fracasso PM, Aghajanian C. A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2020 01; 156(1):13-22. PMID: 31708167.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    32. Moore KN, Gunderson CC, Sabbatini P, McMeekin DS, Mantia-Smaldone G, Burger RA, Morgan MA, Kapoun AM, Brachmann RK, Stagg R, Farooki A, O'Cearbhaill RE. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019 08; 154(2):294-301. PMID: 31174889.
      Citations: 53     Fields:    Translation:HumansCellsCTClinical Trials
    33. Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019 05; 20(5):636-648. PMID: 30948273.
      Citations: 220     Fields:    Translation:HumansCTClinical Trials
    34. Gillen J, Richardson D, Moore K. Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Curr Oncol Rep. 2019 02 26; 21(3):22. PMID: 30806847.
      Citations: 16     Fields:    Translation:HumansAnimals
    35. Moore K, Chan JK, Secord AA, Patel MR, Callahan T, Guo W, Zhang ZY. Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Cancer Chemother Pharmacol. 2019 04; 83(4):717-726. PMID: 30680521.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    36. Moore KN, Pignata S. Trials in progress: IMagyn050/GOG 3015/ENGOT-OV39. A Phase III, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer. 2019 Jan 10. PMID: 30630885.
      Citations: 22     Fields:    
    37. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 12 27; 379(26):2495-2505. PMID: 30345884.
      Citations: 1073     Fields:    Translation:HumansCTClinical Trials
    38. Shenolikar R, Durden E, Meyer N, Lenhart G, Moore K. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States. Gynecol Oncol. 2018 11; 151(2):190-195. PMID: 30268525.
      Citations: 13     Fields:    Translation:Humans
    39. Zargari A, Du Y, Heidari M, Thai TC, Gunderson CC, Moore K, Mannel RS, Liu H, Zheng B, Qiu Y. Prediction of chemotherapy response in ovarian cancer patients using a new clustered quantitative image marker. Phys Med Biol. 2018 08 06; 63(15):155020. PMID: 30010611.
      Citations: 18     Fields:    Translation:Humans
    40. Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 10; 151(1):46-52. PMID: 30093227.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    41. Aghajanian C, Filiaci V, Dizon DS, Carlson JW, Powell MA, Secord AA, Tewari KS, Bender DP, O'Malley DM, Stuckey A, Gao J, Dao F, Soslow RA, Lankes HA, Moore K, Levine DA. A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol. 2018 08; 150(2):274-281. PMID: 29804638.
      Citations: 49     Fields:    Translation:HumansCTClinical Trials
    42. Hong DS, Moore K, Patel M, Grant SC, Burris HA, William WN, Jones S, Meric-Bernstam F, Infante J, Golden L, Zhang W, Martinez R, Wijayawardana S, Beckmann R, Lin AB, Eng C, Bendell J. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clin Cancer Res. 2018 07 15; 24(14):3263-3272. PMID: 29643063.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    43. Moore KN, Birrer MJ. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. Oncologist. 2018 06; 23(6):697-703. PMID: 29593098.
      Citations: 6     Fields:    Translation:Humans
    44. Virani NA, Thavathiru E, McKernan P, Moore K, Benbrook DM, Harrison RG. Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182. PMID: 29574275.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    45. Moore KN, Mirza MR, Matulonis UA. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecol Oncol. 2018 04; 149(1):214-220. PMID: 29397193.
      Citations: 26     Fields:    Translation:Humans
    46. Moore K, Zhang ZY, Agarwal S, Burris H, Patel MR, Kansra V. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer. Cancer Chemother Pharmacol. 2018 03; 81(3):497-503. PMID: 29322231.
      Citations: 11     Fields:    Translation:Humans
    47. Ricci S, Tergas AI, Long Roche K, Fairbairn MG, Levinson KL, Dowdy SC, Bristow RE, Lopez M, Slaughter K, Moore K, Fader AN. Geographic disparities in the distribution of the U.S. gynecologic oncology workforce: A Society of Gynecologic Oncology study. Gynecol Oncol Rep. 2017 Nov; 22:100-104. PMID: 29201989.
      Citations: 16     
    48. Moore KN, Tritchler D, Kaufman KM, Lankes H, Quinn MCJ, Van Le L, Berchuck A, Backes FJ, Tewari KS, Lee RB, Kesterson JP, Wenham RM, Armstrong DK, Krivak TC, Bookman MA, Birrer MJ. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 11; 147(2):396-401. PMID: 28935272.
      Citations: 4     Fields:    Translation:Humans
    49. Danala G, Thai T, Gunderson CC, Moxley KM, Moore K, Mannel RS, Liu H, Zheng B, Qiu Y. Applying Quantitative CT Image Feature Analysis to Predict Response of Ovarian Cancer Patients to Chemotherapy. Acad Radiol. 2017 10; 24(10):1233-1239. PMID: 28554551.
      Citations: 21     Fields:    Translation:Humans
    50. Chakraborty PK, Mustafi SB, Xiong X, Dwivedi SKD, Nesin V, Saha S, Zhang M, Dhanasekaran D, Jayaraman M, Mannel R, Moore K, McMeekin S, Yang D, Zuna R, Ding K, Tsiokas L, Bhattacharya R, Mukherjee P. MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634. PMID: 28530221.
      Citations: 80     Fields:    Translation:HumansAnimalsCells
    51. Grabosch S, Tseng G, Edwards RP, Lankes HA, Moore K, Odunsi K, Vlad A, Ma T, Strange M, Brozick J, Lugade A, Omilian A, Bshara W, Stuckey AR, Walker JL, Birrer M. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2017 07; 146(1):137-145. PMID: 28483269.
      Citations: 2     Fields:    Translation:Humans
    52. Wang Y, Qiu Y, Thai T, Moore K, Liu H, Zheng B. A two-step convolutional neural network based computer-aided detection scheme for automatically segmenting adipose tissue volume depicting on CT images. Comput Methods Programs Biomed. 2017 Jun; 144:97-104. PMID: 28495009.
      Citations: 31     Fields:    Translation:Humans
    53. Gillen J, Gunderson C, Greenwade M, Rowland M, Ruskin R, Ding K, Crim A, Walter A, White E, Moore K. Contribution of age to clinical trial enrollment and tolerance with ovarian cancer. Gynecol Oncol. 2017 04; 145(1):32-36. PMID: 28087143.
      Citations: 1     Fields:    Translation:Humans
    54. Moore K, Brewer MA. Endometrial Cancer: Is This a New Disease? Am Soc Clin Oncol Educ Book. 2017; 37:435-442. PMID: 28561715.
      Citations: 77     Fields:    Translation:Humans
    55. Wang Y, Qiu Y, Thai T, Moore K, Liu H, Zheng B. Applying a computer-aided scheme to detect a new radiographic image marker for prediction of chemotherapy outcome. BMC Med Imaging. 2016 08 31; 16(1):52. PMID: 27581075.
      Citations: 3     Fields:    Translation:Humans
    56. Moore KN, Java JJ, Slaughter KN, Rose PG, Lanciano R, DiSilvestro PA, Thigpen JT, Lee YC, Tewari KS, Chino J, Seward SM, Miller DS, Salani R, Moore DH, Stehman FB. Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. Gynecol Oncol. 2016 Nov; 143(2):294-301. PMID: 27542967.
      Citations: 23     Fields:    Translation:Humans
    57. Atri M, Zhang Z, Dehdashti F, Lee SI, Ali S, Marques H, Koh WJ, Moore K, Landrum L, Kim JW, DiSilvestro P, Eisenhauer E, Schnell F, Gold M. Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial. Gynecol Oncol. 2016 Sep; 142(3):413-9. PMID: 27178725.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    58. Moore KN, Monk BJ. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer. Oncologist. 2016 08; 21(8):954-63. PMID: 27256873.
      Citations: 14     Fields:    Translation:Humans
    59. Moore K, Stone R, Walter A. Society of Gynecologic Oncology 2016 Annual Meeting: Highlights and context. Gynecol Oncol. 2016 06; 141(3):416-420. PMID: 27138457.
      Citations: 1     Fields:    Translation:Humans
    60. Wang Y, Thai T, Moore K, Ding K, McMeekin S, Liu H, Zheng B. Quantitative measurement of adiposity using CT images to predict the benefit of bevacizumab-based chemotherapy in epithelial ovarian cancer patients. Oncol Lett. 2016 Jul; 12(1):680-686. PMID: 27347200.
      Citations: 10     
    61. Mueller JJ, Holzapfel M, Han CH, Santos K, Gunderson C, Moore K, Erickson B, Leath CA, Diaz E, Walsh C, Wethington SL, Dejbakhsh SZ, Barakat RR, Gardner GJ, Hyman DM, Soslow RA, Leitao MM. Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. Int J Gynecol Cancer. 2016 Jan; 26(1):120-4. PMID: 26509849.
      Citations: 10     Fields:    Translation:Humans
    62. Qiu Y, Tan M, McMeekin S, Thai T, Ding K, Moore K, Liu H, Zheng B. Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis. Acta Radiol. 2016 Sep; 57(9):1149-55. PMID: 26663390.
      Citations: 15     Fields:    Translation:Humans
    63. Moore KN, Mannel RS. Is the NCI MATCH trial a match for gynecologic oncology? Gynecol Oncol. 2016 Jan; 140(1):161-6. PMID: 26586415.
      Citations: 10     Fields:    Translation:Humans
    64. Moore KN, Sill MW, Tenney ME, Darus CJ, Griffin D, Werner TL, Rose PG, Behrens R. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. Gynecol Oncol. 2015 Sep; 138(3):513-8. PMID: 26171911.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    65. Zighelboim I, Ali S, Lankes HA, Backes F, Moore K, Mutch D, Robison K, Behbakht K, Waggoner S, Ghebre RG, Pearl M, Ramirez NC, Goodfellow P. Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Sep; 138(3):614-9. PMID: 26144601.
      Citations: 4     Fields:    Translation:HumansCells
    66. Kizer NT, Hatem H, Nugent EK, Zhou G, Moore K, Heller P, Mutch DG, Thaker PH. Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets. Int J Gynecol Cancer. 2015 Jul; 25(6):1015-22. PMID: 26098089.
      Citations: 10     Fields:    Translation:HumansCells
    67. Moore KN, Rowland MR. Treatment Advances in Locoregionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree That More Is Not Always Better? J Clin Oncol. 2015 Jul 01; 33(19):2125-8. PMID: 25987695.
      Citations: 6     Fields:    Translation:Humans
    68. Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun; 137(3):485-9. PMID: 25838164.
      Citations: 7     Fields:    Translation:HumansPHPublic Health
    69. Mannel RS, Moore K. Research: An event or an environment? Gynecol Oncol. 2014 Sep; 134(3):441-2. PMID: 25199577.
      Citations: 3     Fields:    Translation:Humans
    70. Moore K, Infante JR, Cotreau MM, Wilson L, Strahs AL, Vargo DL, Chadha M. A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors. Clin Pharmacol Drug Dev. 2014 07; 3(4):284-9. PMID: 27128834.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    71. Perry LJ, Mathews C, Nugent E, Farrell R, Zorn K, Moore K. Outcomes of cervical cancer and positive para-aortic lymph nodes in the modern era of chemoradiation. Int J Gynecol Cancer. 2014 Mar; 24(3):564-9. PMID: 24552890.
      Citations:    Fields:    Translation:Humans
    72. Pant S, Burris HA, Moore K, Bendell JC, Kurkjian C, Jones SF, Moreno O, Kuhn JG, McMeekin S, Infante JR. A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014 Feb; 32(1):87-93. PMID: 23525756.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    73. Simpkins F, Papadia A, Kunos C, Michener C, Frasure H, AbuShahin F, Mariani A, Bakkum-Gamez JN, Landrum L, Moore K, Thomas SG, Windhorn A, Rose PG. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion. Int J Gynecol Cancer. 2013 Jan; 23(1):98-104. PMID: 23221731.
      Citations: 15     Fields:    Translation:Humans
    74. Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, Cardenes HR, Mannel RS, Farley JH, Schilder RJ, Fracasso PM. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecol Oncol. 2012 Dec; 127(3):456-61. PMID: 22960004.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    75. Moore KN, Tian C, McMeekin DS, Thigpen JT, Randall ME, Gallion HH. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis. Cancer. 2010 Dec 01; 116(23):5407-14. PMID: 20737572.
      Citations: 8     Fields:    Translation:Humans
    76. Rasool N, Fader AN, Seamon L, Neubauer NL, Shahin FA, Alexander HA, Moore K, Moxley K, Secord AA, Kunos C, Rose PG, O'Malley DM. Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence. Gynecol Oncol. 2010 Jan; 116(1):10-4. PMID: 19875158.
      Citations: 14     Fields:    Translation:Humans
    77. Moore KN, Frank SG, Alward EK, Landrum LM, Myers TK, Walker JL, Gold MA, McMeekin DS, Vesely SK, Mannel RS. Adjuvant chemotherapy for the "oldest old" ovarian cancer patients: can we anticipate toxicity-related treatment failure in a vulnerable population? Cancer. 2009 Apr 01; 115(7):1472-80. PMID: 19235786.
      Citations: 1     Fields:    Translation:Humans
    78. Moore KN, Reid MS, Fong DN, Myers TK, Landrum LM, Moxley KM, Walker JL, McMeekin DS, Mannel RS. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply? Gynecol Oncol. 2008 Aug; 110(2):133-9. PMID: 18495221.
      Citations: 21     Fields:    Translation:Humans
    79. Moore KN, Bannon RJ, Lanneau GS, Zuna RE, Walker JL, Gold MA. Cervical dysplasia among women over 35 years of age. Am J Obstet Gynecol. 2008 Nov; 199(5):471.e1-5. PMID: 18486088.
      Citations: 6     Fields:    Translation:Humans
    80. Moore KN, Gold MA, McMeekin DS, Walker JL, Rutledge T, Zorn KK. Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes. Gynecol Oncol. 2008 Mar; 108(3):466-71. PMID: 18191994.
      Citations: 1     Fields:    Translation:Humans
    81. Moore KN, Moxley KM, Fader AN, Axtell AE, Rocconi RP, Abaid LN, Cass IA, Rose PG, Leath CA, Rutledge T, Blankenship D, Gold MA. Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol. 2007 Dec; 107(3):398-403. PMID: 17997146.
      Citations: 10     Fields:    Translation:Humans
    82. Moore K, Cofer A, Elliot L, Lanneau G, Walker J, Gold MA. Adolescent cervical dysplasia: histologic evaluation, treatment, and outcomes. Am J Obstet Gynecol. 2007 Aug; 197(2):141.e1-6. PMID: 17689626.
      Citations: 23     Fields:    Translation:Humans
    83. Moore KN, Lanneau GS, Smith C, Lanneau M, Walker JL, Gold MA, Scott McMeekin D. Pathologic findings and outcomes for octogenarians presenting with uterine malignancy. Gynecol Oncol. 2007 Sep; 106(3):572-8. PMID: 17618678.
      Citations: 3     Fields:    Translation:Humans
    84. Lanneau GS, Skaggs V, Moore K, Stowell S, Zuna R, Gold MA. A LEEP cervical conization is rarely indicated for a two-step discrepancy. J Low Genit Tract Dis. 2007 Jul; 11(3):134-7. PMID: 17596756.
      Citations:    Fields:    Translation:Humans
    85. Moore KN, Gold MA, McMeekin DS, Zorn KK. Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma. Gynecol Oncol. 2007 Sep; 106(3):498-501. PMID: 17561235.
      Citations: 18     Fields:    Translation:Humans
    86. Moore KN, Herzog TJ, Lewin S, Giuntoli RL, Armstrong DK, Rocconi RP, Spannuth WA, Gold MA. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007 May; 105(2):299-303. PMID: 17303230.
      Citations: 24     Fields:    Translation:Humans
    87. Chi DS, Abu-Rustum NR, Sonoda Y, Ivy J, Rhee E, Moore K, Levine DA, Barakat RR. The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers. Am J Obstet Gynecol. 2005 May; 192(5):1614-9. PMID: 15902166.
      Citations: 34     Fields:    Translation:Humans
    88. Abu-Rustum NR, Gemignani ML, Moore K, Sonoda Y, Venkatraman E, Brown C, Poynor E, Chi DS, Barakat RR. Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy. Gynecol Oncol. 2003 Nov; 91(2):402-9. PMID: 14599873.
      Citations: 28     Fields:    Translation:Humans
    Moore's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (297)
    Explore
    _
    Co-Authors (30)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _